pharma news today glp-1 obesity drugs A $60 billion industry just found its next growth lever. 💊 With the expiry of a key patent on March 20, 2026, Indian majors are launching generic weight-loss and diabetes WHO GLP-1 Treatments: WHO Endorses

The brand-name version, Adipex-P, costs around $110 per month but offers no clinical advantage over generics

Billings, MD, MMSc The next steps involve launching Phase 3 clinical trials, which will study eloralintide in a much larger and more diverse group of participants to further examine eloralintides effectiveness and long-term safety, she added

Implications of low muscle mass across the continuum of care: a narrative review

Pernod Ricard reported weaker sales in the United States and China and has been cutting costs and selling non-core assets

higher dose semaglutide may soon be approved for obesity, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape

Food & Drug Administration (FDA) required a safety label for Ozempic (semaglutide) warning of the potential risk of ileus, a condition characterized by impaired intestinal motility